Topical Timolol: a Comparison of Surgical Outcomes
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
The use of topical beta-blockers, such as 0.25% timolol, in promoting wound healing is
currently emerging in the literature. The investigators will enroll 30 participants in a
split scar study who have their skin cancer surgically removed resulting in a linear wound
equal to or longer than 4cm. The objective of this randomized study is to determine the
safety and efficacy of 0.25% timolol in promoting wound healing in wound closed primarily
greater than or equal to 1.5 cm.